Evidence-Based Integrative Hormone Health for Everyone

Evidence-Based Integrative Hormone Health, Menopause, Androgen Optimization, and Chiropractic Care: A Modern, Patient-Centered Guide

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through the latest evidence on hormone health for all individuals, including what the Women’s Health Initiative actually showed, why the choice of molecule and delivery route matters, and how bioidentical 17?-estradiol and micronized progesterone differ from older synthetic hormones. I explain the physiology of estrogen, progesterone, testosterone, and thyroid hormones; how first-pass hepatic metabolism alters clotting and inflammation; and why transdermal estradiol often carries a safer thrombotic profile. I also unpack the androgen receptor saturation model in prostate care, testosterone’s roles in mood, energy, and cognition, and the careful use of testosterone after prostate cancer. Throughout, I show how integrative chiropractic care—spinal manipulation, soft-tissue work, breathing mechanics, strength programming, sleep optimization, and nutrition—amplifies endocrine benefits by modulating autonomic tone, pain, and movement quality.

Why physiology, molecule choice, and integration matter

When patients meet me for the first time, they often carry a simple question underneath complex symptoms: what is going wrong, and how do we fix it safely? Over years of practice in chiropractic, family medicine, and functional integrative care, I’ve learned that durable outcomes emerge when we respect the body’s signaling logic. Hormones are master communicators: tissues express receptors for a reason, and when those receptors sit silent—because ligands decline or signaling pathways are disrupted—systems drift. My care starts by restoring physiologic signals with the right molecules, in the right routes, at the right doses, and at the right time. Then I reinforce those gains through integrative chiropractic care that reduces nociception, improves autonomic balance, and enables progressive movement.

Key points I will cover:

• What the Women’s Health Initiative actually tested and why route and molecule matter
• Why bioidentical 17?-estradiol and micronized progesterone differ from conjugated equine estrogens and synthetic progestins
• How first-pass hepatic metabolism shifts coagulation and inflammatory tone
• Why transdermal estradiol reduces venous thromboembolism risk compared to oral estrogen in many patients
• How progesterone’s neuroactive metabolites support sleep and calm
• Testosterone’s roles in mood, energy, sexual function, cognition, and musculoskeletal health for all individuals
• The androgen receptor saturation model and modern evidence on prostate health and post-cancer testosterone therapy
• How integrative chiropractic care aligns mechanics with endocrine signaling to amplify outcomes

Hormone signaling 101: receptors set the rules

I consider hormones to be messages that need the right mailbox. Receptors translate those messages into intracellular cascades that change gene expression, mitochondrial output, membrane trafficking, and structural remodeling. If a cell expends energy to express a receptor, activating it within physiologic ranges is usually beneficial. Symptoms of deficiency often reflect quiet receptors: the mailbox is present, but no mail is delivered.

• Estrogen receptors ER? and ER? coordinate synaptic plasticity, endothelial function, bone remodeling, and immune balance. They shape autonomic tone, insulin sensitivity, and neurovascular coupling (Levin & Hammes, 2016).
• Progesterone receptors PR-A and PR-B support GABAergic modulation, myelination, control of neuroinflammation, and endometrial differentiation—key to sleep and emotional steadiness (Brinton et al., 2008).
• Androgen receptors drive protein synthesis, mitochondrial biogenesis, erythropoiesis, and insulin sensitivity; these underpin mood, vigor, libido, and physical performance (Traish, 2020).
• Thyroid receptors TR?/? are nearly ubiquitous, setting basal metabolic rate and oxidative capacity; when thyroid tone slips, nearly every organ system feels it (Mullur et al., 2014).

Clinical takeaway: restore the orchestra. Correcting deficiencies is less about choosing a favorite hormone and more about rebalancing the network so signals reach receptors at the right time.

The WHI revisited: what was tested and why route matters

The Women’s Health Initiative (WHI) triggered headlines that scared millions: hormones increase breast cancer and cardiovascular risk. But the main treatments tested were oral conjugated equine estrogen (CEE) and CEE plus medroxyprogesterone acetate (MPA)—not the Oral administration mandated first-pass hepatic metabolism, upregulating coagulation factors and C-reactive protein. That single design choice meaningfully altered physiology and risk (The North American Menopause Society, 2022; Manson et al., 2013; Anderson et al., 2012).

• Why are delivery route changes risky?
  • Oral estrogens enter the portal vein first, stimulating hepatic production of clotting factors II, VII, IX, X, and fibrinogen and increasing CRP, tilting hemostasis toward coagulation.
  • Transdermal 17?-estradiol bypasses the liver initially, yields steadier estradiol, maintains more physiologic estradiol-to-estrone ratios, and produces minimal change in clotting factors—lowering observed venous thromboembolism risk in comparative studies (Canonico et al., 2007; Scarabin, 2018).
• What later WHI analyses showed
  • In women who had a hysterectomy and took estrogen alone (CEE), longer follow-up indicated a lower rate of breast cancer cases and deaths; most early worries came from using CEE with MPA.
  • Extrapolating those oral, legacy molecules to all forms of hormone therapy is scientifically unsound. Molecules and routes matter.

Clinical takeaway: the WHI did not test modern transdermal 17?-estradiol paired with micronized progesterone. Route- and molecule-specificity should guide modern care.

Why 17?-estradiol and bioidentical progesterone are different

When I choose estrogen therapy, I prefer bioidentical 17?-estradiol—ideally transdermal. As the native ligand, estradiol engages ER?/ER? with the co-regulators nature expects, producing tissue-selective gene programs in the brain, vessels, bone, and fascia. Estradiol enhances endothelial nitric oxide synthase activity, improves flow-mediated dilation, and modulates vascular stiffness; these benefits are compromised if the liver’s first-pass signaling simultaneously raises coagulation tone (Levin & Hammes, 2016; The North American Menopause Society, 2022).

• Why transdermal estradiol
  • Bypasses first-pass hepatic stimulation of clotting proteins; steady pharmacokinetics reduce symptom volatility, sleep disruption, and mood lability.
  • Observational cohorts show lower signals of venous thromboembolism compared with oral forms, especially in higher-risk populations (Canonico et al., 2007; Scarabin, 2018).
• Progesterone vs. progestins
  • Micronized progesterone binds PR-A/B with physiologic conformations, stabilizes the endometrium, and its neuroactive metabolites (notably allopregnanolone) promote deeper sleep and anxiolysis (Brinton et al., 2008; Prior, 2018).
  • Synthetic progestins (e.g., MPA, norethindrone acetate) can bind to androgenic, glucocorticoid, and mineralocorticoid receptors, leading to off-target effects on lipids, mood, and vascular function. This receptor promiscuity helps explain conflicting risk signals (Stuenkel et al., 2015; The North American Menopause Society, 2022).
• Breast health nuance
  • Evidence suggests micronized progesterone does not share the same breast risk patterns seen with certain progestins when combined with estrogen. In clinical practice, it offers endometrial protection and neurophysiologic benefits with favorable tolerability (Anderson et al., 2012; The North American Menopause Society, 2022; Prior, 2018).

Physiology of cyclic hormones: estradiol builds; progesterone differentiates

Estradiol proliferates and primes; progesterone stabilizes and differentiates. In the follicular phase, rising estradiol supports endometrial growth and vascular architecture. After ovulation, progesterone peaks about 1 week later, reducing mitosis and preparing the tissue for implantation. Withdrawal triggers organized shedding. Clinically, estradiol and progesterone are synergistic teammates, not enemies. We also consider testosterone, thyroid hormones, cortisol, insulin, and cytokines—the entire web must be mapped for effective dosing.

Transdermal vs. oral estrogen: portal physiology and coagulation

The first-pass hepatic metabolism of oral estradiol increases markers of inflammation and coagulation, which changes the risk of venous thromboembolism. Transdermal delivery bypasses the portal route and helps maintain lipids, CRP, and clotting parameters more stably. In patients with migraine with aura, obesity, prior VTE, thrombophilias, or antiphospholipid antibodies, transdermal estradiol at the lowest effective dose is typically safer (The North American Menopause Society, 2022; Stuenkel et al., 2015; Canonico et al., 2007).

Practical monitoring:

• Dose titration to relieve vasomotor symptoms while protecting bone, brain, and connective tissue
• Track blood pressure, lipids, glucose/A1C, hs-CRP, and individual markers like Lp(a) when indicated

Testosterone: a human hormone with brain-body reach

Testosterone is central in both sexes. Women synthesize testosterone and benefit from its neuro-musculoskeletal actions; men depend on it for mood, sexual function, energy, strength, and cognition. Physiologically, testosterone supports mitochondrial biogenesis, protein synthesis, endothelial nitric oxide bioavailability, and dopaminergic tone (Traish, 2020; Snyder et al., 2016; Corona et al., 2014).

• In women
  • Carefully titrated low-dose testosterone can improve libido, vigor, and training response in selected cases, with vigilant monitoring to avoid virilization and lipid disruptions (Islam et al., 2019).
  • In my experience, pairing low-dose testosterone with strength training, sleep optimization, and protein adequacy often allows minimal dosing to achieve meaningful function.
• In men
  • Mood, sexual function, and energy are consistently improved when deficiency is corrected, as shown in randomized trials and meta-analyses (Snyder et al., 2016; Corona et al., 2014).
  • I treat reversible drivers first (sleep apnea, obesity, medications) and use physiologic dosing with tight safety monitoring.

The saturation model: prostate health and testosterone therapy

For years, clinicians feared testosterone would fuel prostate cancer. Modern evidence supports the androgen receptor saturation model: at relatively low serum testosterone, prostatic androgen receptors are near-maximally occupied; beyond that, increasing circulating testosterone does not proportionately stimulate prostate tissue or PSA (Morgentaler & Traish, 2009).

Clinical implications:

• If a man’s baseline testosterone is already above saturation, raising testosterone within physiologic ranges rarely increases prostatic stimulation.
• After definitive treatment for prostate cancer and with stable or undetectable PSA, selected men can consider physiologic testosterone therapy under urologic co-management and vigilant monitoring (Pastuszak et al., 2013; Morgentaler et al., 2016).

Cardiovascular safety: modern meta-analyses and trials

Early testosterone safety concerns often reflected heterogeneous methods and confounding. Contemporary meta-analyses and large trials indicate that physiologic hormone replacement in hypogonadal men, when selected and monitored appropriately, does not increase the risk of major adverse cardiovascular events and can improve sexual function and correct anemia (Corona et al., 2018; Hudson et al., 2022; Nissen et al., 2023).

Practical safety steps I use:

• Stratify baseline cardiovascular risk and optimize blood pressure, lipids, and glycemia
• Screen and treat sleep apnea
• Monitor hematocrit/hemoglobin, estradiol, lipids, liver enzymes, PSA (as appropriate), and blood pressure at regular intervals
• Prefer transdermal or short-acting modalities initially for adjustability

Cognition and testosterone: neuroprotection signals

The brain is rich in androgen receptors. Observational data suggest men in the lowest testosterone quintiles have a higher incident dementia risk compared with higher quintiles. While association is not causation, mechanistic data—reduced neuroinflammation, improved cerebral perfusion, and synaptic support—support a protective role for adequate sex steroid tone (Hsu et al., 2019; Westlye et al., 2023).

My clinical approach:

• Screen cognition-sensitive domains early and address sleep-disordered breathing, insulin resistance, hypertension, and dyslipidemia
• Combine hormone optimization with resistance training and aerobic intervals, sleep hygiene, anti-inflammatory nutrition, and cognitive training to stack neuroprotective effects

Integrative chiropractic care: aligning mechanics, autonomics, and endocrine signals

Hormone therapy works best in a body that moves and rests well. Integrative chiropractic care modulates nociceptive input, autonomic balance, and kinetic chain function to amplify endocrine benefits.

What I do:

• Spinal manipulation and low-force mobilization to restore segmental motion and reduce dorsal horn nociception—lowering central sensitization and improving proprioceptive integration
• Instrument-assisted soft tissue mobilization and myofascial release to normalize extracellular matrix gliding and stimulate collagen remodeling affected by hormonal shifts
• Breathing mechanics training—diaphragmatic sequencing, paced respiration around six breaths per minute—to elevate vagal tone, reduce vasomotor symptoms, and consolidate sleep
• Progressive resistance training programs (hip hinge, squat, push, pull, carry) to counter anabolic resistance, build bone, and improve insulin sensitivity
• Nutrition coaching: protein targets of 1.2–1.6 g/kg/day, omega-3 emphasis, and micronutrients (vitamin D, magnesium, vitamin K2)

Why these techniques matter:

• Reducing nociception and improving movement unlocks adherence to exercise prescriptions that drive endocrine, bone, and metabolic gains
• Autonomic recalibration reduces sympathetic overdrive and inflammation, allowing hormones to act on a calmer physiologic terrain
• Tissue remodeling aligns with estradiol and testosterone’s effects on fibroblasts, tendons, and osteocytes

Clinical observations from my practice align with these mechanisms. When I combine transdermal estradiol and nighttime micronized progesterone with spinal manipulation, soft-tissue work, and progressive strength training, I see faster resolution of neck and low back pain, fewer tendinopathies, improved training tolerance, and better cognitive stamina. I share case patterns and ongoing commentary on my platforms: Chiropracticscientist.com and LinkedIn. These day-to-day outcomes mirror the modern literature on physiology—normalizing signaling, improving mechanics, stabilizing sleep, and increasing resilience.

Bone health: density, microarchitecture, and hormone-mechanical synergy

Healthy bone is dynamic—a living matrix remodeled by osteoclasts and osteoblasts under the guidance of sex steroids, mechanical loading, and nutrient signaling. Estrogen restrains osteoclastogenesis by modulating RANKL/OPG and preserves osteocyte viability; testosterone supports osteoblast activity directly and through aromatization to estradiol in men (Khosla & Monroe, 2018).

My standard protocol for bone loss:

• Restore physiologic estrogen in women or testosterone in men when indicated, and monitor carefully
• Program progressive resistance and impact loading to activate mechanotransduction pathways, decrease sclerostin, and turn on Wnt/?-catenin signaling (Lau et al., 2022)
• Optimize vitamin D and K2 for mineral trafficking and osteocalcin carboxylation, and magnesium for matrix synthesis
• Hit protein targets to supply collagen substrate

Clinical outcome: Patients who commit to hormone optimization, structured loading, and nutrition typically show stabilization or improvement in BMD on DEXA scans, with fewer falls and injuries. These observations align with broader evidence that combined therapy outperforms monotherapy (Eastell et al., 2019).

Testing strategy: use labs to inform decisions, not dictate them

I employ serum testing for consistency, using sensitive assays when available:

• Women: estradiol (E2), progesterone (context-dependent), CBC, CMP, fasting lipids, A1C, hs-CRP; consider thyroid panel, vitamin D, ferritin, iron studies, Lp(a) when indicated
• Men: total and free testosterone (equilibrium dialysis or reliable calculation with SHBG), estradiol (LC-MS/MS preferred), LH/FSH, prolactin, CBC, CMP, lipids (ApoB), A1C, hs-CRP, thyroid panel, PSA as appropriate

Interpretation principles:

• Symptoms and function trump rigid thresholds; free hormone levels matter when SHBG is elevated
• I titrate dosing to clinical response and safety parameters rather than chasing a single number

Practical protocol: stepwise, individualized care

• Clarify goals and symptoms
  • Vasomotor symptoms, sleep, cognition, mood, sexual function, weight, musculoskeletal pain
• Stratify risk
  • Personal and family history of VTE, stroke, breast/gynecologic/prostate cancers, thrombophilias, migraines with aura, and autoimmune conditions
• Select molecules and routes
  • Prefer transdermal 17?-estradiol; pair with oral micronized progesterone at night for women with a uterus
  • Consider carefully titrated testosterone for men with biochemical hypogonadism and symptoms; in women, use low-dose off-label therapy with informed consent and vigilant monitoring
• Integrate chiropractic and lifestyle interventions
  • Spinal manipulation, regional mobility, gait retraining, progressive strength, breathing drills, sleep optimization
• Monitor and adapt
  • Reassess at 6–12 weeks for symptoms and labs; adjust dose, delivery, and adjunct therapies

Addressing common myths with evidence

• Myth: estrogen causes breast cancer
  • Reality: molecule, route, dose, and context determine risk. Estrogen-alone therapy in specific WHI cohorts associated with lower breast cancer incidence and mortality on extended follow-up; combined CEE/MPA drove early signals (Anderson et al., 2012; Manson et al., 2013).
• Myth: progesterone and progestins are interchangeable
  • Reality: micronized progesterone differs meaningfully from synthetic progestins in receptor specificity, tolerability, and metabolic effects (Stuenkel et al., 2015; The North American Menopause Society, 2022).
• Myth: oral vs. transdermal estrogen is the same
  • Reality: first-pass hepatic metabolism changes coagulation, inflammation, and lipoproteins, shifting risk (Canonico et al., 2007; Scarabin, 2018).
• Myth: testosterone therapy necessarily fuels prostate cancer or cardiovascular events
  • Reality: the saturation model and modern meta-analyses support physiologic dosing with careful selection and monitoring; cardiovascular outcomes are neutral to favorable in properly managed hypogonadal men (Morgentaler & Traish, 2009; Hudson et al., 2022; Nissen et al., 2023).

Why each technique is used: mechanistic rationale

• Transdermal 17?-estradiol
  • To deliver the native ligand with minimal hepatic coagulation signaling and steady neurovascular effects (The North American Menopause Society, 2022)
• Micronized progesterone at night
  • To stabilize the endometrium and enhance sleep via allopregnanolone’s GABA-A modulation, deeper sleep improves insulin sensitivity, pain thresholds, and mood (Brinton et al., 2008; Prior, 2018)
• Spinal manipulation
  • To reduce segmental dysfunction, modulate dorsal horn signaling, and improve proprioceptive input—essential for therapeutic exercise and central pain processing
• Soft-tissue and fascia-focused care
  • To address altered connective tissue turnover under changing hormonal milieus, restoring glide and load-sharing reduces pain and improves movement economy
• Strength training
  • To counter anabolic resistance, build bone density, and improve insulin sensitivity, muscle is an endocrine organ that releases myokines supporting systemic anti-inflammatory signaling (Pedersen & Febbraio, 2012)
• Breathing and autonomic retraining
  • To reduce sympathetic drive, improve HRV, and stabilize vasomotor and sleep symptoms

Clinical scenarios I commonly see

• Perimenopausal athlete with Achilles tendinopathy
  • Transdermal estradiol, nighttime progesterone, instrument-assisted soft tissue mobilization, eccentric loading, and calf-hip strength progressions; outcome—reduced pain, restored training volume, fewer relapses
• Postmenopausal professional with insomnia and neck pain
  • Micronized progesterone at night, low-dose transdermal estradiol, cervical-thoracic manipulation, rib mobility, paced breathing; outcome—sleep consolidation, fewer cervicogenic headaches
• Hypogonadal man with cardiometabolic risk and low energy
  • Physiologic testosterone with sleep apnea screening, progressive resistance training, protein-forward nutrition, and thoracic mobility work; outcome—higher vigor, improved glycemia, better training adherence

My clinical observations and ongoing work

I publish case-based commentary that maps physiology to function across the spine, fascia, and endocrine systems. Patients who balance hormone treatment with integrative chiropractic care often experience faster symptom relief and longer-lasting results. You can explore my ongoing insights and case trends at my site, Chiropracticscientist.com, and on my professional LinkedIn profile.

Closing perspective: receptors are invitations to heal

Receptors are the body’s invitations—biochemical requests for beneficial action. Age, stress, illness, and iatrogenesis often silence those invitations. By restoring bioidentical hormones with the right routes and doses and by aligning mechanics, sleep, nutrition, and autonomic function through integrative chiropractic care, we reconnect signaling networks from mitochondria to mind. With modern evidence, careful monitoring, and whole-person strategies, I see consistent improvements in sleep, mood, sexual function, bone density, strength, pain, and cardiometabolic health. This is what evidence-based, patient-centered practice looks like: physiology first, technique chosen for mechanism, and integration for durability.

References

• The 2022 hormone therapy position statement of The North American Menopause Society (The North American Menopause Society, 2022).
• Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women’s Health Initiative randomized trials (Manson et al., 2013).
• Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: Long-term follow-up of the Women’s Health Initiative randomized trial (Anderson et al., 2012).
• Postmenopausal hormone therapy and risk of venous thromboembolism: Results from the E3N cohort study (Canonico et al., 2007).
• Progestogens and venous thromboembolism among postmenopausal women using hormone therapy (Scarabin, 2018).
• Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline (Stuenkel et al., 2015).
• Progesterone for symptom control and endometrial protection (Prior, 2018).
• Nuclear receptors outside the nucleus: Extranuclear signalling by steroid receptors (Levin & Hammes, 2016).
• Progesterone receptors: Form and function in brain (Brinton et al., 2008).
• Testosterone and weight loss: The evidence (Traish, 2020).
• Thyroid hormone regulation of metabolism (Mullur et al., 2014).
• Testosterone implants in women: A safe therapy for breast cancer prevention? (Glaser et al., 2014).
• Testosterone therapy in men with treated and untreated prostate cancer: Impact on oncologic outcomes (Morgentaler et al., 2016).
• Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth (Morgentaler & Traish, 2009).
• Effects of testosterone treatment in older men (Snyder et al., 2016).
• Testosterone supplementation and sexual function: A meta-analysis study (Corona et al., 2014).
• Adverse cardiovascular events and mortality in men during testosterone treatment: An individual patient and aggregate data meta-analysis (Hudson et al., 2022).
• Cardiovascular safety of testosterone-replacement therapy (Nissen et al., 2023).
• Longitudinal relationships between reproductive hormones and cognitive decline in older men (Hsu et al., 2019).
• Sex hormones and brain aging: Large-scale population imaging studies (Westlye et al., 2023).
• Regulation of bone metabolism by sex steroids (Khosla & Monroe, 2018).
• Osteocyte mechanobiology (Lau et al., 2022).
• Muscles, exercise and obesity: Skeletal muscle as a secretory organ (Pedersen & Febbraio, 2012).
• The 2022 hormone therapy position statement of The North American Menopause Society (duplicate citation retained for emphasis in clinical sections).

Author and clinical insights

• Clinical perspectives and case-based observations: https://chiropracticscientist.com/
• Professional background and updates: https://www.linkedin.com/in/dralexjimenez/